Long-term supplementation of NAD+ boosters such as Nicotinamide Riboside and Nicotinamide Mononucleotide have been demonstrated to increase lifespan in animal models.
Human clinical trials are ongoing, with published papers demonstrating:
- Safety and increase in NAD+ levels. (1,2)
- Insulin sensitivity unchanged. (1)
- Cardiac biomarkers seem to improve. (3)
Will a systematic review of human trials conclude by 2030 that NAD+ boosting is effective in increasing human lifespan by >5%?
This question will resolve positive if at any point until 2030 a systematic review of clinical trials of NAD+ boosting will explicitly mention a lifespan improvement of at least 5% in humans. (results in animal models or lifespan estimation based on results in treatment of diseases are not enough for positive resolution)